Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed—a physiologically based pharmacokinetic analysis
Our work demonstrates that apixaban would not be a suitable agent for breastfeeding women during the postnatal period, while rivaroxaban shows significant promise due to low infant exposure and warrants further investigation.
Authors
- Jignesh P. Patel (ORCID: https://orcid.org/0000-0003-4197-8294)
- Roopen Arya (ORCID: https://orcid.org/0000-0001-5630-7990)
- Andrew S. Butler (ORCID: https://orcid.org/0000-0003-4362-940X)
- Susan Cole
Institutions
- Environment Agency (GB)
- King's College Hospital NHS Foundation Trust (GB)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1016/j.jtha.2025.09.040
- Citations
- 1
- Primary Topic
- Cardiovascular Issues in Pregnancy
- Type
- article
- Field-Weighted Citation Impact
- 1.39